Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by MasterAlgaeon May 01, 2021 12:21pm
430 Views
Post# 33108464

Will amalgamation be a catalyst?

Will amalgamation be a catalyst?In and of itself I'd say no. But it sets the stage.
Currently the market cap is just over $191,000,000
We need just under a $151,000,000 catalyst to get the market capitalization to the point where the intrinsic value of the warrants of the ($6.00) bought deal are close to having value.
In other words - for the warrants to get close to having any value would mean a MC of about $342,750,000....But that is based on the current number of shares outstanding, so the numbers are low by 15%..?
The terms of the IP dilution are likely built into the share price. At least we hope so.

The catalyst(s) will be the work that was done by Stern IR to advance Antibe's capital markets strategy (assuming they were effective), the groundwork that was being done by Antibe in large market partnering, and the work done by Antibe in preparing their pipeline expansion initiatives.
That's what we should expect to see after the announcement of the amalgamation.
 
<< Previous
Bullboard Posts
Next >>